Bayram Fahri, Unluhizarci Kursad, Kelestimur Fahrettin
Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Treat Endocrinol. 2002;1(1):45-53. doi: 10.2165/00024677-200201010-00005.
Polycystic ovary syndrome (PCOS) is a form of functional ovarian hyperandrogenism. It is one of the most common endocrinologic disorders in women of reproductive age. Women with PCOS may present with menstrual irregularities, chronic anovulation, infertility, obesity and hyperandrogenism. PCOS is associated with insulin resistance and hyperinsulinemia in most, if not all, patients. Besides its gynecological manifestations, PCOS is also associated with increased metabolic and cardiovascular risks. These risks are strongly linked to insulin resistance, and during recent years a novel therapeutic approach using insulin-sensitizing agents has been extensively investigated. In most studies conducted to date, metformin and the thiazolidinedione agent troglitazone have resulted in improved insulin sensitivity, resumption of regular menses and decreased serum androgen levels. Insulin-sensitizing agents may be a useful adjuvant therapy for women with PCOS.
多囊卵巢综合征（PCOS）是一种功能性卵巢雄激素过多症。它是育龄女性中最常见的内分泌疾病之一。患有PCOS的女性可能会出现月经不规律、慢性无排卵、不孕、肥胖和雄激素过多。在大多数（如果不是全部）患者中，PCOS与胰岛素抵抗和高胰岛素血症有关。除了其妇科表现外，PCOS还与代谢和心血管风险增加有关。这些风险与胰岛素抵抗密切相关，近年来，一种使用胰岛素增敏剂的新型治疗方法已得到广泛研究。在迄今为止进行的大多数研究中，二甲双胍和噻唑烷二酮类药物曲格列酮已使胰岛素敏感性提高、月经恢复正常且血清雄激素水平降低。胰岛素增敏剂可能是PCOS女性有用的辅助治疗方法。
